Comparative Pharmacology
Head-to-head clinical analysis: BILTRICIDE versus EMVERM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BILTRICIDE versus EMVERM.
BILTRICIDE vs EMVERM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Praziquantel increases the permeability of cell membranes to calcium ions in susceptible schistosomes and other trematodes, causing sustained contraction and paralysis of the worm musculature, leading to detachment from blood vessel walls and eventual death.
Mebendazole binds to tubulin, inhibiting microtubule polymerization, which disrupts glucose uptake and causes energy depletion leading to parasite death.
60 mg/kg/day orally in 3 divided doses (20 mg/kg/dose) for 1 day.
Mebendazole 100 mg orally twice daily for 3 days for adults and children over 2 years.
None Documented
None Documented
Terminal elimination half-life is approximately 0.8-1.5 hours for praziquantel; clinical significance: short half-life necessitates multiple dosing for sustained antiparasitic effect.
2-8 hours; clinical context: the short half-life supports once-daily dosing; metabolites may persist longer.
Renal excretion accounts for approximately 80-90% of elimination, primarily as metabolites; biliary/fecal excretion is minor (<10%).
Primarily fecal (approx. 90%) as unchanged drug and metabolites; <10% excreted renally.
Category C
Category C
Anthelmintic
Anthelmintic